Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

21 January 2020

Antibiotikaresistenzen: Zu viel vom Falschen

Thomas Trappe of Tagesspiegel writes about the launch of the new Antimicrobial Resistance Benchmark during the 2020 World Economic Forum in Davos.

Direct links

Read the full article

The article begins with a quote from Jayasree K Iyer, Executive Director of the Access to Medicine Foundation:

We are losing ground both with the new antibiotics and with those that have existed for a long time.

The article then dives into the results of the 2020 Antimicrobial Resistance Benchmark, covering topics like antibacterial R&D, forgotten antibiotics progress in responsible promotion, and tracking the spread of resistance. It highlights the top performing companies in these areas. 

The article states that Iyer hopes for support from the German Chancellor to help tackle AMR. Angela Merkel, says Iyer, will meet the heads of several pharmaceutical companies at the World Economic Forum currently taking place in Davos: Here, she can urge them to invest more in the development of antibiotics and the fight against antibiotic resistance.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved